The National Comprehensive Cancer Network (NCCN) today announces the publication of NCCN Guidelines for Patients: Hodgkin Lymphoma in Children.
Can your child see the blackboard at school? Ophthalmologist Marcela Maria Estrada explains why kids often don’t know they have bad eyesight and gives tips for healthy vision.
The Center for Immunization and Infection Research in Cancer at Moffitt Cancer Center is expanding its viral infection research in Africa. The cancer center has received a $5.5 million, five-year specialized research center grant (U54CA277834) from the National Cancer Institute to investigate virus-associated tumors that disproportionately impact men and women living with HIV in sub-Saharan Africa.
The University of Texas MD Anderson Cancer Center was awarded four grants totaling nearly $4.9 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the expansion of physical activity programs for survivors, the dissemination of targeted tobacco cessation programs and the recruitment of a first-time, tenure-track faculty member.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Joann B. Sweasy, PhD, has been elected to serve as vice president/president-elect of AACI’s Board of Directors. Three new board members were also chosen: Edward Chu, MD, MMS; Raymond N. DuBois, MD, PhD; and Yolanda Sanchez, PhD.
The National Comprehensive Cancer Network expands materials tailored for the MENA region to help improve patient outcomes by standardizing local cancer care; includes new adaptation focused on genetic/familial cancer risk, as well as care for ovarian/fallopian tube/primary peritoneal cancers.
In a new study published and included on the cover of the journal Cancer Research, Moffitt Cancer Center researchers demonstrate how mathematical modeling combined with dynamic biomarkers can be used to characterize metastatic disease and identify appropriate therapeutic approaches to improve patient outcomes.
The Food and Drug Administration announced yesterday the approval of HEPZATO Kit to treat ocular melanoma that has spread to the liver. HEPZATO uses a hepatic delivery system to inject the chemotherapy drug melphalan into the liver, a procedure referred to as percutaneous hepatic perfusion (PHP). Moffitt Cancer Center’s Jonathan S. Zager, M.D., was the lead international principal investigator on the multinational FOCUS phase 3 clinical trial to test the procedure, which is manufactured by Delcath Systems, Inc.
Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative to accelerate and expand UT Austin’s burgeoning medical district into a world-class academic medical center for education, research and patient care. The University of Texas at Austin Medical Center will start with two new hospital towers -- The University of Texas MD Anderson Cancer Center and a UT Austin hospital. MD Anderson, the nation’s #1 cancer hospital, will expand its Houston footprint to Austin by building and operating a new, comprehensive cancer center, while UT Austin will build and operate its new specialty hospital.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Adrienne Phillips, MD, MPH, as director of Cell Therapy and Bone Marrow Transplantation Northern Regions at New Jersey’s leading cancer program and only National Cancer Institute (NCI)- Designated Comprehensive Cancer Center.
Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS), together with other collaborating groups, have discovered the first lipid vascular ‘ZIP code’ in the lungs, with implications for improved diagnostics and treatments, including patients with severe human respiratory diseases such as emphysema, COVID-19, COPD and lung cancer.
Penile squamous cell carcinoma is a rare form of penile cancer with limited treatment options. An international study led by Yale Cancer Center researchers at Yale School of Medicine finds that the use of immune checkpoint inhibitors (ICIs) offers promising clinical benefits for some patients with advanced penile squamous cell carcinoma.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Niketa C. Shah, MD, as chief of Pediatric Bone Marrow Transplantation and Cellular Therapies at New Jersey’s leading cancer program.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.
Breast cancer screening for women over 70 is not without risks, according to new research from Yale School of Medicine’s COPPER Center. Although some guidelines recommend continuing screening for older women, a new study emphasizes the importance of assessing potential harms associated with testing, such as overdiagnosis, which, researchers say, can negatively affect quality of life.
JNCCN study sheds light on a rapid shift in practice evolution by oncologists treating people with colon cancer adjuvantly after primary surgery, following publications from the IDEA collaboration.
Damon Reed, MD, has joined Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Head of the Division of Pediatric Solid Tumors and as Chief of the Pediatric Sarcoma Service.
The New Mexico Cancer Care Alliance (NMCCA) has rebranded as the New Mexico Cancer Research Alliance (NMCRA) to strengthen its focus on delivering cancer clinical trials to New Mexicans. Through the NMCRA’s unique collaboration, every New Mexican has access to cancer clinical trials. Cancer clinical trials test new treatments and new methods of delivering and improving cancer care.
One common side effect of treatment for ovarian cancer is chemotherapy-induced peripheral neuropathy (CIPN), which can damage peripheral nerves, causing severe pain and numbness. The effects can last for months – or even years — after completing chemotherapy. Currently, there is only one treatment with limited efficacy for CIPN.
Researchers at Dana-Farber Cancer Institute have created an AI-based tool that uses tumor gene sequencing data to predict the primary source of a patient’s cancer. The study, published in in Nature Medicine, suggests that this predictive tool, called OncoNPC, could help guide treatment of cancer and improve outcomes in difficult to diagnose cases.
A Ludwig Cancer Research study has identified a pair of genes whose expression by a type of immune cell within tumors is predictive of outcomes for cancer patients and is linked to a vast network of gene expression programs, engaged by multiple cell types in the tumor microenvironment, that control human cancers.
Targeted therapies have revolutionized cancer treatment and the field of oncology. The FDA has approved over 70 targeted therapies for various cancer types, including lung cancer. Epidermal growth factor receptor (EGFR) mutations are found in a significant proportion of lung adenocarcinomas, and the use of tyrosine kinase inhibitors (TKIs) such as osimertinib, have improved patient outcomes.
The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, M.D., an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search. His appointment is effective Sept. 1.
Smilow Cancer Hospital at Yale New Haven is ranked as one of the highest hospitals for cancer care in the country by U.S. News & World Report. This year, Smilow Cancer Hospital at Yale New Haven is listed in the top 50 in the nation and is number 1 in Connecticut. "We are proud to be recognized as one of the leading cancer hospitals in our country,” said Eric Winer, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. Reporting on wildfire smoke? Fred Hutch clinicians and researchers are available to their expertise. Dr. Trang VoPham is an epidemiologist focusing on environmental exposures and risk, follow her on social media.
20240208171546.png&width=400&height=400)
Memorial Sloan Kettering Cancer Center has been recognized as the best cancer center in the northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2023-24 “Best Hospitals” survey. The institution has been one of the nation’s top two hospitals for cancer care since the survey’s inception in 1990.
Human papillomavirus (HPV) has been linked to a significant increase in cancers of the throat and tonsils over the past few decades; this is projected to become the most common form of head and neck cancer by 2030. But a major limitation to reducing treatment intensity is the inability to correctly identify the patients whose HPV-related cancers will be the most responsive to treatment.
Pilot awards, pre-doctoral fellowship awards and post-doctoral awards totaling $1.5 million were recently awarded to Rutgers Cancer Institute of New Jersey investigators by the New Jersey Commission on Cancer Research (NJCCR).
A report summarizing the results of a series of surveys distributed to AACI cancer center members was published in the Journal of the National Cancer Institute (JNCI) Cancer Spectrum.
Immune-checkpoint inhibitors have become the standard of care for patients with advanced melanoma to improve survival, but only some patients respond to this immunotherapy and have long-term benefits. The lack of a long-lasting response, researchers say, is related to failure of antitumor immunologic memory. Treatment options for advanced melanoma are limited for patients who do not respond to this type of therapy.
Chimeric antigen receptor (CAR)-T cells are a powerful, new form of cancer therapy that are being studied to treat blood cancers. Using a new approach, Yale Cancer Center researchers at Yale School of Medicine found a new way to substantially improve the effectiveness of CAR-T cell therapy. The new study was published in Nature Immunology on July 27.
Moffitt Cancer Center has appointed Paulo Rodriguez, Ph.D., chair of the Department of Immunology and co-leader of the Immuno-Oncology Program.
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.
MD Anderson and Nexo announced a strategic research collaboration to rapidly advance new cancer therapies against previously undruggable targets.
Volunteering in late life is associated with better cognitive function — specifically, better executive function and episodic memory, according to a new UC Davis study.
It's fragile X awareness month, and the NIH has renewed funding for a key study of the neurodegenerative condition fragile X-associated tremor ataxia syndrome (FXTAS).
The Cancer Research Institute awarded $28.7 million in research grants and fellowships in the 2023 fiscal year ending June 30, 2023. In total, CRI distributed 73 awards that will advance cancer immunology research at 41 institutions in 10 countries. CRI grants were awarded to support projects involving a variety of immune-based approaches as well as the development of novel technologies that may help pave the way for the next generation of immunotherapies.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A Moffitt Cancer Center researcher, in collaboration with investigators at the National Institutes of Health, are working to answer that question for the nearly 4 million breast cancer survivors in the United States. In their newest study, they found that compared to cancer-free women, breast cancer survivors experience a faster rate of aging.
The University of Texas MD Anderson Cancer Center today announced a $16.25 million gift from Howard and Susan Elias to accelerate brain tumor and cancer neuroscience research, an emerging field focused on integrating the role of the nervous system in cancer.
Thousands of people will come together on Saturday, Aug. 12, in Seattle, Washington, for Obliteride, Fred Hutchinson Cancer Center’s annual bike ride, 5K walk/run and fundraiser.
While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.
Fern Lazar, Managing Partner and Global Health Practice Leader at FINN Partners, was elected to the Cancer Research Institute’s Board of Trustees.
Moffitt Cancer Center has named Brian D. Gonzalez, Ph.D., as the inaugural associate center director of Research Diversity and Workforce Development. In the new role, Gonzalez will lead efforts to increase diversity among Moffitt’s research faculty, staff and trainees, working in collaboration with the offices of Enterprise Equity; Community Outreach, Engagement & Equity; and Research Education & Training. He will also develop and implement the cancer center’s Plan to Enhance Diversity. This initiative is a new requirement from the National Cancer Institute to show that the workforce of an NCI-designated cancer center reflects the populations of the communities that it serves.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
